A Parkinson’s experiment suggests another way to protect vulnerable neurons

Neurodegeneration and regenerative biology · Source date: October 30, 2026 · Evidence: Preclinical nonhuman-primate disease model · Primary source

The nervous system depends on ways to remove damaged proteins. One of these, chaperone-mediated autophagy, uses the lysosomal protein LAMP2A to help process selected cellular cargo. Parkinson’s disease is linked to abnormal alpha-synuclein. A new Science Advances study tested whether raising LAMP2A expression could blunt damage caused by injections of patient-derived Lewy-body material in nonhuman primates.

The investigators report protection of dopamine-producing neurons, delayed accumulation or release of pathology-related alpha-synuclein species, and favorable motor and cognitive behavior in the primate model. The animals did not have naturally developing human Parkinson’s disease, and neither human efficacy nor an acceptable gene-delivery risk profile is established.

The next question is whether the approach can be delivered safely and restore function in people with established disease. Protecting neurons in an induced model does not establish clinical benefit in Parkinson’s disease.